Johnson & Johnson (NYSE: JNJ) held its JNJ Q2 2026 earnings call on July 15, 2026, during which executives highlighted a dense slate of late-stage pipeline catalysts spanning prostate cancer, bladder cancer, and immunology, while also announcing plans to acquire FireFly Bio to expand the company's oncology platform. Management also fielded pointed questions about the timing risk attached to the pivotal milvexian program in atrial fibrillation.
Johnson & Johnson reported worldwide sales of USD 25.3 billion for the quarter, up 5.6% year-on-year (YOY) operationally, and raised full-year 2026 operational sales growth guidance to a range of 6.5% to 7.1%. Adjusted operational earnings per share guidance was increased to USD 11.50– USD 11.65, with CFO Joseph Wolk noting the outlook excludes any impact from pending acquisitions such as FireFly Bio.
Key Strategic Signals
Milvexian AFib trial remains event-driven with no fixed readout date: John Reed, Executive Vice President of Innovative Medicine Research and Development, confirmed the Phase III atrial fibrillation studies for milvexian are fully recruited but event-driven, meaning the timing depends on when a sufficient number of clinical events accrue rather than a calendar date. Reed said the data monitoring committee "keeps saying, go full steam ahead", and cited confidence in the Phase II-derived dosing schedule, but the readout could land anywhere from late 2026 to early 2027. Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, framed the opportunity around an estimated 18 million people who could benefit from oral anticoagulation but are currently undertreated due to bleeding risk with existing agents.
ICOTYDE expansion into inflammatory bowel disease and psoriatic arthritis progresses in parallel with launch: Reed said pivotal data for ICOTYDE in psoriatic arthritis are expected later this year, while Phase III studies in ulcerative colitis and Crohn's disease are underway, positioning the oral IL-23 inhibitor as a potential frontline therapy across a broader set of immune-mediated indications than its initial psoriasis approval.
FireFly Bio acquisition adds KRAS-targeting antibody platform: Following the earlier acquisition of Halda Therapeutics, J&J announced plans to acquire FireFly Bio in June, adding what Wolk described as a proprietary platform designed to target KRAS-driven solid tumors. The deal, expected to close in the third quarter, extends a pattern of using bolt-on acquisitions to diversify the oncology pipeline beyond the company's established myeloma and lung cancer franchises
Analyst Pressure Points
- Wolfe Research's Alexandria Hammond pressed management on milvexian's risk-reward profile, noting the size and breadth of the program could produce outcomes ranging from a clean win to a miss, and asked whether the trial remained on track for a 2026 readout. Reed acknowledged the event-driven design prevents a firm timeline commitment, saying the company can only "wait for the events," while reiterating that the data monitoring committee has continued to recommend proceeding without modification.
- TD Cowen's Michael Nedelcovych challenged the TREMFYA narrative by asking why AbbVie's SKYRIZI has held share in gastrointestinal indications despite TREMFYA's apparent competitive edge. Taubert did not directly address SKYRIZI's resilience but pointed to TREMFYA's induction share leadership in ulcerative colitis (58%) and Crohn's disease (over 50%) among IL-23 inhibitors, along with new FUZION study data in perianal fistulizing Crohn's disease, an indication she said no other IL-23 inhibitor has demonstrated efficacy in.
Forward-Looking Catalysts
- Pasritamig and JNJ-6143 prostate cancer readouts, expected in the second half of 2026, represent the first clinical data points for two distinct modalities in advanced prostate cancer. Pasritamig is a bispecific antibody targeting patients who have progressed after multiple prior lines of therapy, while JNJ-6143 is an oral therapy for metastatic castration-resistant disease and marks the first clinical readout from the Halda Therapeutics acquisition, giving investors an early signal on that deal's clinical translation.
- The milvexian Phase III atrial fibrillation readout remains the single largest binary catalyst in the pipeline, given the scale of the anticoagulation market and the company's stated ambition to address a population of patients currently unable to tolerate existing therapies due to bleeding risk. No fixed date exists, but management indicated the studies are fully enrolled and awaiting sufficient clinical events.
Access the AllSci platform to explore the science behind the news.
Spot something wrong? Report an issue with this article
